Filtered By:
Condition: Thrombosis
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 508 results found since Jan 2013.

Successful Treatment with t-PA of a Stroke Patient after Reversal of Dabigatran with Idarucizumab (P3.291)
Conclusions:We report the first successful treatment with t-PA of an acute stroke patient after reversal of dabigatran with idarucizumab.Disclosure: Dr. Cossey has nothing to disclose. Dr. Reddy has nothing to disclose. Dr. Savitz has received research support from the NIH. Dr. Grotta has received personal compensation for activities with Frazer and Stryker. Dr. Grotta has received research support from Genentech and Medtronic.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cossey, T., Reddy, S., Savitz, S., Grotta, J. Tags: Cerebrovascular Disease Case Reports II Source Type: research

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients Arrhythmia and Electrophysiology
ConclusionsRivaroxaban therapy was associated with a statistically significant increase in all‐cause death compared with dabigatran therapy in atrial fibrillation patients.
Source: JAHA:Journal of the American Heart Association - April 24, 2017 Category: Cardiology Authors: Lai, C.-L., Chen, H.-M., Liao, M.-T., Lin, T.-T., Chan, K. A. Tags: Arrhythmias, Anticoagulants, Pharmacology, Cerebrovascular Disease/Stroke Original Research Source Type: research

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants Expert opinion of the Societe Francaise de Neurologie Vasculaire (SFNV) French Vascular Neurology Society and the Groupe Francais d'etudes sur l'Hemostase et la Thrombose (GFHT) French study Group on Haemostasis and Thrombosis
ConclusionsIn this expert opinion paper, we suggest that IVT can be performed in patients selected according to the time elapsed since the drug was last taken, renal function, type of hospital where the patient is admitted and plasma concentration of DOAC.This article is protected by copyright. All rights reserved.
Source: European Journal of Neurology - January 23, 2018 Category: Neurology Authors: Emmanuel Touz é, Yves Gruel, Isabelle Gouin‐Thibault, Emmanuel De Maistre, Sophie Susen, Pierre Sie, Laurent Derex Tags: Original Article Source Type: research

Novel oral anticoagulants in non-valvular atrial fibrillation
Atrial fibrillation (AF) confers a significant risk of stroke or systemic thromboembolism. Oral anticoagulation is the most effective therapy for AF-related stroke prevention. A decision to advise oral anticoagulation should be based upon the individual absolute risks of stroke and bleeding, and almost all AF patients with ≥1 stroke risk factors have a positive net clinical benefit of oral anticoagulation.The novel oral anticoagulants (NOACs) dabigatran, rivaroxaban and apixaban are more convenient, and are at least equally effective and safer (regarding bleeding complications) for stroke prevention compared with vitamin...
Source: Best Practice and Research. Clinical Haematology - June 1, 2013 Category: Hematology Authors: Tatjana S. Potpara, Gregory Y.H. Lip Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-Analyses.
Abstract PURPOSE: The findings from the observational studies comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) for atrial fibrillation (AF) and venous thromboembolism (VTE) are inconsistent. We conducted separate meta-analyses examining the efficacy/effectiveness and safety of NOACs versus VKAs by disease (AF vs VTE), study design (randomized controlled trials [RCTs] vs observational studies), and NOAC (dabigatran, rivaroxaban, apixaban, and edoxaban). METHODS: The main data sources included PubMed/MEDLINE, EMBASE, Web of Scienc...
Source: Clinical Therapeutics - June 28, 2017 Category: Drugs & Pharmacology Authors: Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH Tags: Clin Ther Source Type: research

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
The objective of this study was to compare effectiveness and safety between reduced dose DOACs and high TTR warfarin treatment (TTR  ≥ 70%) in NVAF. A Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 40,564 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) (11,083 patients) or warfarin treatment (29,481 patients ) after exclusion of 374,135 patients due to not being warfarin or DOAC naïve, not being prescribed reduced dose, having previous mechanical heart valve (MHV), or being under 18 years old. The me...
Source: Journal of Thrombosis and Thrombolysis - January 6, 2023 Category: Hematology Source Type: research

Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population
AbstractAtrial fibrillation (AF) prevalence increases with age;>  80% of US adults with AF are aged ≥ 65 years. Compare the risk of stroke/systemic embolism (SE), major bleeding (MB), net clinical outcome (NCO), and major adverse cardiac events (MACE) among elderly non-valvular AF (NVAF) Medicare patients prescribed direct oral anticoagulants (DOACs)vs warfarin. NVAF patients aged ≥ 65 years who initiated DOACs (apixaban, dabigatran, and rivaroxaban) or warfarin were selected from 01JAN2013-31DEC2015 in CMS Medicare data. Propensity score matching was used to balance DOAC and warfarin cohorts. Cox proportion...
Source: Journal of Thrombosis and Thrombolysis - June 29, 2019 Category: Hematology Source Type: research

Practical management of patients on apixaban: a consensus guide
Conclusions: The predictable pharmacokinetics and minimal drug interactions of apixaban should allow for safe anticoagulation in the majority of patients, including temporary interruption for elective procedures. In the absence of published data, patients actively bleeding on apixaban should receive standard supportive treatment. Quantitative assays of apixaban level such as chromogenic anti-Xa assays are becoming available but their utility is unproven in this setting. Specific antidotes for novel anticoagulants, including apixaban, are in clinical development.
Source: Thrombosis Journal - December 31, 2013 Category: Hematology Authors: Christopher WardGreg ConnerGeoffrey DonnanAlexander GallusSimon McRae Source Type: research

A pulmonary vein thrombus in a patient with autonomic nervous dysfunction
Publication date: Available online 8 May 2015 Source:IJC Heart & Vasculature Author(s): Hidekazu Takeuchi Ischemic stroke is a serious clinical problem, and preventing ischemic stroke is an important clinical target. Left atrial thrombus is a known cause of ischemic stroke. In 2015, I reported that nearly all left atrial thrombi result from a pulmonary vein thrombus (PVT), indicating that PVT is associated with ischemic stroke. However, the relationship between PVT and autonomic nervous function is unknown. Although PVT is believed to be rare, since 2012, I have reported several cases of PVT in elderly patients w...
Source: IJC Heart and Vasculature - May 9, 2015 Category: Cardiology Source Type: research

Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation
Conclusion Left atrial appendage closure in NVAF in a real-world setting may result in lower stroke and major bleeding rates than reported in LAAC clinical trials. Left atrial appendage closure in both settings achieves cost parity in a relatively short period of time and may offer substantial savings compared with current therapies. Savings are most pronounced among higher risk patients and those unsuitable for anticoagulation.
Source: European Heart Journal - December 29, 2016 Category: Cardiology Authors: Panikker, S., Lord, J., Jarman, J. W. E., Armstrong, S., Jones, D. G., Haldar, S., Butcher, C., Khan, H., Mantziari, L., Nicol, E., Hussain, W., Clague, J. R., Foran, J. P., Markides, V., Wong, T. Tags: Thrombosis and antithrombotic therapy Source Type: research

‘Ten Commandments’ of the EHRA Guide for the Use of NOACs in AF
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF), and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. In 2013, the first “EHRA Practical Guide” was published to provide practical guidance for situations; an update was published in 2015. Below ...
Source: European Heart Journal - April 21, 2018 Category: Cardiology Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis
ConclusionsIn pooled, analyzed randomized controlled trials and observational studies, DOACs were associated with better efficacy in early CKD, as well as similar efficacy and safety outcomes to warfarin in patients with CKD stages 4 –5 or dialysis patients. The results of patients with CKD stages 4–5 and dialysis patients were from observational studies. Well-designed randomized controlled trials focused on DOAC use in patients with CKD and dialysis patients are needed.PROSPERO register number: CRD42020150599, 6 February, 2020.
Source: Clinical Drug Investigation - March 11, 2021 Category: Drugs & Pharmacology Source Type: research

Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases
ConclusionsIn this real-world analysis of a large sample of NVAF patients with prior bleeding, NOACs were associated with similar or lower risk of stroke/SE and MB vs. warfarin and variable risk of stroke/SE and MB against each other.
Source: Journal of Thrombosis and Thrombolysis - May 17, 2022 Category: Hematology Source Type: research